Enduring Material

• Examine the details of chronic pain, its prevalence, and its mechanism in psoriatic arthritis and spondyloarthritis.
• Review what may cause fatigue, ways to assess fatigue and treatment options.
• Understand the impact of chronic pain and fatigue on people living with rheumatic diseases.

Pain and Fatigue: Overview, Diagnosis and Management in patients with PsA and SpA

• Philip Mease, MD - Director, Rheumatology Research Swedish Medical Center/Providence St. Joseph Health; and Clinical Professor of Medicine at the University of Washington in Seattle
• Ernest Choy, MD - Head of Rheumatology and Translational Research at the Division of Infection and Immunity and Director of the Cardiff Regional Experimental Arthritis Treatment and Evaluation (CREATE) Centre at Cardiff University School of Medicine, Cardiff, Wales, UK
• Melissa Leeolou - Stanford University
• Minionette Wilson - Patient Consultant and the Spondylitis Association of America (SAA) Support Group Co-Leader in Raleigh/Durham, North Carolina

• The National Psoriasis Foundation designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The National Psoriasis Foundation designates this enduring material for a maximum of 0.75 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Managing chronic pain and fatigue in patients with PsA and SpA can be challenging for providers. Hear rheumatologists Dr. Philip Mease (Director, Rheumatology Research Swedish Medical Center/Providence St. Joseph Health) and Dr. Ernest Choy (Cardiff University School of Medicine), and patients Melissa Leeolou and Minionette “Mini” Wilson discuss causes, symptoms, risks and the latest in managing chronic pain and fatigue successfully. This is the second of three CME episodes in CAPES (Clinician and Patient Education Series) presented by NPF, GRAPPA, SPARTAN and SAA. This program is supported by an educational grant from Pfizer Inc.

Ernest Choy, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Abbvie, Amgen, Biogen, Biocon, Chugai Pharma, Eli Lilly, Fresenius Kai, Galapagos, Janssen, Gilead, Pfizer, RPharm, Sanofi-Aventis, and UCB - Consulting - Relationship Has Not Ended
• Abbvie, Amgen, Biogen, Biocon, Chugai Pharma, Eli Lilly, Fresenius Kai, Galapagos, Janssen, Gilead, Pfizer, RPharm, Sanofi-Aventis, and UCB - Speaking - Relationship Has Not Ended
• Abbvie, Amgen, Biogen, Biocon, Chugai Pharma, Eli Lilly, Fresenius Kai, Galapagos, Janssen, Gilead, Pfizer, RPharm, Sanofi-Aventis, and UCB - Advisory Committee Member - Relationship Has Not Ended
• Bio-Cancer, Biogen, Novartis, Pfizer, Roche, Sanofi - Contracted Research - Relationship Has Not Ended

Melissa Leeolou has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Janssen, Bristol Myers Squibb - Consulting - Relationship Has Not Ended
• Novartis - Consulting - Relationship Ended

Philip Mease, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• AbbVie, Aclaris, Amgen, Boehringer lngelheim, Brlstol Myers Squibb, Eli Lillv, Galapagos, Gilead, GlaxosmithKline, lnmagene, Janssen, Novartis, Pfizer, Sun Pharma, UCB - Consulting - Relationship Has Not Ended
• AbbVie, Amgen, Brlstol Myers Squibb, Eli Lillv, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, UCB - Contracted Research - Relationship Has Not Ended
• AbbVie, Amgen, Eli Lillv, Janssen, Novartis, Pfizer, UCB - Speaking - Relationship Has Not Ended

Minionette Wilson has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Janssen - Consulting - Relationship Ended
• Janssen - Advisory Committee Member - Relationship Ended

Hemalatha Srinivasalu, MD has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Joerg Ermann, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Eli Lilly, Pfizer, UCB - Consulting - Relationship Has Not Ended
• Eli Lilly, Pfizer, UCB - Advisory Committee Member - Relationship Has Not Ended
• AbbVie, Novartis, UCB - Research and Grant Funding - Relationship Has Not Ended

Maureen Dubreuil, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• UCB - Advisory Committee Member - Relationship Ended
• Amgen - Advisory Committee Member - Relationship Has Not Ended

Philip Mease, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• AbbVie, Aclaris, Amgen, Boehringer lngelheim, Brlstol Myers Squibb, Eli Lillv, Galapagos, Gilead, GlaxosmithKline, lnmagene, Janssen, Novartis, Pfizer, Sun Pharma, UCB - Consulting - Relationship Has Not Ended
• AbbVie, Amgen, Brlstol Myers Squibb, Eli Lillv, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, UCB - Contracted Research - Relationship Has Not Ended
• AbbVie, Amgen, Eli Lillv, Janssen, Novartis, Pfizer, UCB - Speaking - Relationship Has Not Ended

Judith A Smith, MD, PhD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Novartis - Consulting - Relationship Ended

Any relevant financial relationships have been mitigated.

This activity is supported by an educational grant from Pfizer Inc. Support for this activity is gratefully acknowledged from Pfizer, Inc..

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Psoriasis Foundation and SPARTAN, Spondylitis Association of American and GRAPPA. The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

0 %

100 %

8/25/2022